Kommentar zu „INTERVENTION – HCC: lokale Tumorprogression nach Radiofrequenzablation“

Rofo 2024; 196(02): 122
DOI: 10.1055/a-2173-4892

Brennpunkt

Daniel Gnutzmann

¹Zentrum für Diagnostische und Interventionelle Radiologie, Klinikum Konstanz, Konstanz, Germany

Literatur
1 Nishikawa H, Inuzuka T, Takeda H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143
2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome (Langversion 4.0, August 2023). AWMF-Registernummer: 032–053OL. Zugriff am 07. September 2023 unter: https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome
3 Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol 2020; 43: 402-410
4 Dhanasekaran R, Kooby DA, Staley CA. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480
5 Shi Q, Liu J, Li T. et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. Clin Res Hepatol Gastroenterol 2022; 46: 101893
6 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905